Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The role of CYP3A5 genotypes in dose requirements of tacrolimus and everolimus after heart transplantation.

Clinical transplantation - 1 Jan 2000

Kniepeiss Daniela, Renner Wilfried, Trummer Olivia, Wagner Doris, Wasler Andrä, Khoschsorur Gholam A, Truschnig-Wilders Martie, Tscheliessnigg Karl-Heinz

Abstract excerpt

BACKGROUND: tacrolimus and everolimus are immunosuppressive drugs metabolized by enzymes of the CYP3A subfamily. A common variant of the CYP3A5 gene, CYP3A5*3, results in strongly decreased CYP3A5 activity and has been shown to influence Tacrolimus blood concentrations, but its role for the pharmacogenetics of Everolimus remains unclear. Aim of the study was to examine the role of CYP3A5*3 variant in tacrolimus...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP3A
Share to Everolimus

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Graft Rejection

Share to Heart Diseases

Share to Heart Transplantation

Share to Immunosuppressive Agents

Share to Sirolimus

Share to Tacrolimus

Source

Identifiers

PMID: 20041908
DOI: 10.1111/j.1399-0012.2009.01198.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The role of CYP3A5 genotypes in dose requirements of tacrolimus and everolimus after heart transplantation.PMID 20041908Read ↗

The role of CYP2C8 genotypes in dose requirement and levels of everolimus after heart transplantation.Semantic proximity Read ↗

CYP3A5*3 and POR*28 genetic variants influence the required dose of tacrolimus in heart transplant recipients.Semantic proximity Read ↗

Effect of CYP3A5, CYP3A4, and ABCB1 genotypes as determinants of tacrolimus dose and clinical outcomes after heart transplantation.Semantic proximity Read ↗

Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients.Semantic proximity Read ↗

Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism.Semantic proximity Read ↗

Influence of CYP3A4*22 and CYP3A5*3 combined genotypes on tacrolimus dose requirements in Egyptian renal transplant patients.Semantic proximity Read ↗

The combination of CYP3A4*22 and CYP3A5*3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation.Semantic proximity Read ↗

Impact of the CYP3A5*1 Allele on the Pharmacokinetics of Tacrolimus in Japanese Heart Transplant Patients.Semantic proximity Read ↗

CYP3A5 Gene-Guided Tacrolimus Treatment of Living-Donor Egyptian Kidney Transplanted PatientsSemantic proximity Read ↗

Which Genetic Determinants Should be Considered for Tacrolimus Dose Optimization in Kidney Transplantation? A Combined Analysis of Genes Affecting the CYP3A Locus.Semantic proximity Read ↗

Effects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients.Semantic proximity Read ↗

CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.